FGP
XENE icon

Freestone Grove Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Freestone Grove Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,748
Closed -$271K – 978
2025
Q3 		$271K Buy
+6,748
New +$238K ﹤0.01% 624

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Freestone Grove Partners's XENE Position: Q4 2025 in Review

Freestone Grove Partners sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 6,748 shares — an estimated $271K sold.

Freestone Grove Partners first reported a position in XENE in Q3 2025 and held it in 1 quarter. The position peaked at $271K in Q3 2025. 245 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Freestone Grove Partners reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 6,748 Xenon Pharmaceuticals shares in Q4 2025, an estimated $271K.
  • Freestone Grove Partners first reported a position in Xenon Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Xenon Pharmaceuticals position peaked at $271K in Q3 2025.
  • 245 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.